Polikistik Over Sendromu Tedavisinde İnositol Desteği

İnositol, karbonhidrat familyasına ait bir vitaminoiddir. Biyolojik yönden aktif olan formu Myo-inositol (MI), daha az aktif olan bir diğer stereoizomeri ise MInın epimerizasyonu sonucu oluşan D-Chiro inositol (DCI)dür. MI, tiroid stimüle edici hormon (TSH), folikül stimüle edici hormon (FSH) ve insülin gibi hormonları düzenleyen ikincil mesajcı inositol trifosfatın öncüsüdür. Polikistik over sendromu (PKOS) ise doğurganlık çağındaki bireylerde sıklıkla rastlanmakta olup insülin direnci, hiperandrojenemi ve ovulasyondaki değişikliklerle ilişkilidir. İnositolün insülin direnci üzerine olumlu etkilerinden dolayı PKOS tedavisinde etkili olabileceği düşünülmektedir. Sadece MI uygulanan PKOSlu bireylerde oosit kalitesinde düzelme gözlenirken, MI ve DCI uygulanan bireylerde ise insülin duyarlılığının geliştiği saptanmıştır. DCI, glukoz alımı ve glikojen sentezini düzenleyen ikincil mesajcıları sağlarken, MI, FSH ve glukoz alımı için ikincil mesajcıları üretir. PKOS tedavisinde inositolün iki izomerinin en uygun dozu, MI/DCI oranı 40:1 olarak belirlenmiştir. Bu derleme makalede PKOS tedavisinde inositol desteğinin olumlu etkilerinin incelenmesi amaçlanmıştır.

Inositol Supplementation in Treatment of Polycystic Ovarian Syndrome

Inositol is a vitaminoid belongs to carbohydrate family. Biologically active form of inositol is Myo-inositol (MI) and less active form is another stereoisomer D-chiro inositol (DCI) synthesized by epimerisation of MI. MI is precursor of inositol triphosphate which is second messenger regulating the hormones like follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH) and insulin. Polycistic over syndrome (PCOS) is frequently seen in women in fertility age and associated with insulin resistance, hyperandrogenism and changes in ovulation. Its thought that inositol can be effective in the treatment of PCOS due to its positive effects on insulin resistance. It has been determined that insulin sensitivity was improved in the people with PCOS after administration of MI and/or DCI, while oocyte quality was increased in people only MI administration. MI produces second messengers for FSH and glucose uptake, while DCI provides second messengers for glucose uptake and glycogene synthesis. It has been assessed that MI/DCI ratio should be 40:1 for the optimum dosage in PCOS treatment. In this review article, it was aimed to be investigated positive effects of inositol supplementation in PCOS treatment.

PDF

___

1.Bizzarri M, Carlomagno G. Inositol: history of an effective therapy for polycystic ovary syndrome. Eur Rev Med Pharmacol Sci 2014;18(13):1896-1903.
2.Minozzi M, DAndrea G, Unfer V. Treatment of hirsutism with Myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17(4):579-582.
3.Morgante G, Orvieto R, Di Sabatino A, Musacchio MC, De Leo V. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril 2011; 95(8):2642-2644.
4.Aksoy M. Ansiklopedik Beslenme, Diyet ve Gıda Sözlüğü. 1 bs. Ankara, Hatiboğlu Yayınevi; 2007.
5.Nordio M, Proietti E. The combined therapy with Myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to Myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012; 16(5):575-581.
6.Majumder AL, Biswas BB. Biology of inositols and phosphoinositides. New York, Springer; 2006.
7.Heimark D, McAllister J, Larner J. Decreased Myo- inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2014;61(2):111-117.
8.Parthasarathy LK, Seelan RS, Tobias C, Casanova MF, Parthasarathy RN. Mammalian inositol 3-phosphate synthase: its role in the biosynthesis of brain inositol and its clinical use as a psychoactive agent. Subcell Biochem 2006;39:293-314.
9.Barker CJ. Inositol Phosphates and Lipids: Methods and Protocols. New York, Humana Press; 2012.
10.Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of Myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147(2):120-123.
11.Galletta M, Grasso S, Vaiarelli A, Roseff SJ. Bye- bye chiro-inositol-Myo-inositol: true progress in the treatment of polycystic ovary syndrome and ovulation induction. Eur Rev Med Pharmacol Sci 2011;15(10):1212-1214.
12.Unfer V, Carlomagno G, Papaleo E, Vailati S, Candiani M, Baillargeon JP. Hyperinsulinemia alters myoinositol to D-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014;21(7):854-858.
13.Seo MD, Enomoto M, Ishiyama N, Stathopulos PB, Ikura M. Structural insights into endoplasmic reticulum stored calcium regulation by inositol 1,4,5-trisphosphate and ryanodine receptors. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 2014 [E-pub ahead of print], doi:10.1016/j.bbamcr.2014.11.023.
14.Papaleo E, Unfer V, Baillargeon JP, De Santis L, Fusi F, Brigante C, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecological Endocrinology 2007;23(12):700-703.
15.DSouza K, Epand RM. Enrichment of acyl chains in the lipids of the phosphatidylinositol cycle. Biochim Biophys Acta 2014;1838(6):1501-1508.
16.Aksoy M. Beslenme Biyokimyası. 3. bs. Ankara, Hatiboğlu Yayınları; 2011.
17.Inositol. www.fao.org/docrep/x5738e/x5738e07.htm#1.10. Erişim tarihi: 16.11.2014.
18.Bayraktar A, Akbulut G. Diabetes mellitusun tıbbi beslenme tedavisinde fitik asit: Faydalı mı? Zararlı mı? Gümüşhane University Journal of Health Sciences 2013;2(1):150-168.
19.Mullaney EJ, Ullah AH, Turner B, Richardson A, Mullaney E. Phytases: attributes, catalytic mechanisms and applications. Inositol phosphates: Linking agriculture and the environment 2007;97-110.
20.Genazzani AD, Santagni S, Ricchieri F, Campedelli A, Rattighieri E, Chierchia E, et al. Myo-inositol modulates insulin and luteinizing hormone secretion in normal weight patients with polycystic ovary syndrome. J Obstet Gynaecol Res 2014;40(5):1353-1360.
21.Belmaker RH, Levine J. Inositol in the treatment of psychiatric disorders. Natural Medications for Psychiatric Disorders. Philadelphia: Wolters Kluwer 2008;105-118.
22.Costantino D, Minozzi G, Minozzi E, Guaraldi C. Metabolic and hormonal effects of Myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009;13(2):105-110.
23.Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to Myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012;28(12):969-973.
24.Artini P, Di Berardino O, Papini F, Genazzani A, Simi G, Ruggiero M, et al. Endocrine and clinical effects of Myo-inositol administration in polycystic ovary syndrome. A randomized study. Gynecological Endocrinology 2013;29(4):375-379.
25.Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011;15(8):931- 936.
26.Yasin M, Yasmeen F. Polycystic ovarian syndrome; pattern of disease in patients. Professional Med J 2014;21(1):179-184.
27.Trikudanathan S. Polycystic Ovarian Syndrome. Med Clin North Am 2015;99(1):221-235.
28.Carreau AM, Baillargeon JP. PCOS in adolescence and type 2 diabetes. Curr Diab Rep 2014;15(1):1-9.
29.Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE. Uncoupling between insulin and release of a d-chiro- inositolcontaining inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome. Metab Syndr Relat Disord 2010;8(2):127- 135.
30.Lagana AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-chiro- inositol. Arch Gynecol Obstet 2015;291(5):1181-1186.
31.Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of Myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28(7):509-515.
32.Nestler JE. Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 2008;358(1):47-54.
33.Genazzani AD, Santagni S, Rattighieri E, Chierchia E, Despini G, Marini G, et al. Modulatory role of D-chiro- inositol (DCI) on LH and insulin secretion in obese PCOS patients. Gynecol Endocrinol 2014;30(6):438- 443.
34.Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3(1):47-60.
35.Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, Apridonidze T, Iuorno MJ, Nestler JE. Altered D-chiro- inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29(2):300-305.
36.Cheang KI, Baillargeon JP, Essah PA, Ostlund RE Jr, Apridonize T, Islam L, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57(10):1390-1397.
37.Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95(8):2515- 2516.
38.Chattopadhayay R, Ganesh A, Samanta J, Jana SK, Chakravarty BN, Chaudhury K. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecol Obstet Invest 2010;69(3):197-202.
39.La Marca A, Grisendi V, Dondi G, Sighinolfi G, Cianci A. The menstrual cycle regularization following d-chiro- inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol 2015;31(1):52-56.
40.Kamenov Z, Kolarov G, Gateva A, Carlomagno G, Genazzani AD. Ovulation induction with Myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance. Gynecol Endocrinol 2014;1-5.
41.Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340(17):1314-1320.
42.Iuorno MJ, Jakubowicz DJ, Baillargeon JP, Dillon P, Gunn RD, Allan G, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002;8(6):417-423.
43.Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89(1):242-249.
44.Gerli S, Papaleo E, Ferrari A, Di Renzo GC. Randomized, double blind placebo-controlled trial: effects of Myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11(5):347-354.
45.Zacche MM, Caputo L, Filippis S, Zacche G, Dindelli M, Ferrari A. Efficacy of Myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25(8):508- 513.
46.Papaleo E, Unfer V, Baillargeon JP, Fusi F, Occhi F, De Santis L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91(5):1750-1754.
47.Rizzo P, Raffone E, Benedetto V. Effect of the treatment with Myo-inositol plus folic acid plus melatonin in comparison with a treatment with Myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010;14(6):555-561.
48.DAnna R, Di Benedetto V, Rizzo P, Raffone, Interdonato M, Corrado F. et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012;28(6):440-442.